Spectral AI Completes Data Analysis for U.S. Burn Pivotal Study
Rhea-AI Summary
Spectral AI (NASDAQ: MDAI) has completed data analysis for its U.S. Burn Pivotal Study, one of the largest domestic burn studies ever conducted. The study validates the AI-driven algorithm used in the company's DeepView® System, which received FDA Breakthrough Device Designation in 2018.
The DeepView® System combines multispectral imaging with AI algorithms to predict burn wound healing potential, leveraging over 340 billion clinically-validated data points. The system provides immediate, binary predictions of wound healing on the day of injury, aiding clinical decision-making for treatment.
The company reports strong metrics when comparing the DeepView® System's performance to burn and emergency room physicians in determining wound healing potential. Spectral AI plans to submit a De Novo classification request to the FDA by June 2025 for the system's use in burn care.
Positive
- Completion of data analysis for major U.S. Burn Pivotal Study
- Strong performance metrics compared to physicians in wound healing assessment
- System leverages 340 billion clinically-validated data points
- FDA Breakthrough Device Designation already obtained
- Clear regulatory pathway with De Novo submission planned for June 2025
Negative
- None.
Insights
The completion of data analytics for Spectral AI's U.S. Burn Pivotal Study marks a pivotal moment in burn care innovation. The DeepView® System represents a potential paradigm shift in burn assessment, addressing a critical clinical need for immediate, objective wound healing prediction.
The system's extensive training on 340 billion clinically-validated data points suggests robust algorithm development. The strong sensitivity and specificity metrics versus physician assessments are particularly noteworthy, as accurate early assessment of burn depth and healing potential remains a significant challenge in clinical practice. This technology could potentially reduce unnecessary surgeries and optimize treatment timing, leading to improved patient outcomes and reduced healthcare costs.
The planned De Novo FDA submission by June 2025 follows multiple pre-submission meetings, indicating a well-structured regulatory strategy. The De Novo pathway, while typically longer than 510(k), offers the advantage of establishing a new device classification and potentially creating barriers to entry for competitors. The Breakthrough Device Designation received in 2018 may expedite the review process and support favorable reimbursement decisions.
For healthcare providers and institutions, the system's ability to provide same-day, binary predictions could streamline clinical decision-making and resource allocation. The technology's AI-driven approach aligns with the broader healthcare industry trend toward data-driven, personalized medicine, potentially positioning Spectral AI as a leader in the digital transformation of wound care.
The successful completion of data analysis for the U.S. Burn Pivotal Study represents a significant value inflection point for Spectral AI. The burn care market presents a substantial commercial opportunity, with the global burn care market projected to grow significantly due to increasing industrialization and aging populations.
Several key value drivers emerge from this development:
- The extensive proprietary database of 340 billion data points creates a significant competitive moat and barrier to entry
- The Breakthrough Device Designation could accelerate both FDA review and Medicare coverage determination
- The binary nature of the results and same-day assessment capability present clear value propositions for healthcare providers, potentially driving rapid adoption
- The system's ability to optimize treatment decisions could generate substantial cost savings for healthcare systems, strengthening the reimbursement case
The planned De Novo submission by June 2025 provides investors with a clear regulatory timeline. While the De Novo pathway typically requires more extensive documentation than a 510(k), it offers stronger market protection as the first-of-its-kind device. The multiple pre-submission meetings with FDA suggest a well-defined regulatory strategy, potentially reducing approval risks.
DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the completion of its data analytics for its U.S. Burn Pivotal Study. One of the largest domestic burn studies ever conducted, the U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by the Company’s DeepView® System for its burn indication. Spectral AI's DeepView® System is a predictive medical device and associated software that assesses the healing potential of burn wounds by combining multispectral imaging with an AI-driven algorithm trained and tested against a proprietary database of more than 340 billion clinically-validated data points. By distinguishing between healing and non-healing tissue, the DeepView® System provides an immediate and binary prediction of wound healing on the same day of injury, benefiting clinical decision-making regarding next step treatment.
The Company announced today that it has completed its data analytics and the results reflect strong metrics of the DeepView® System when compared to burn and emergency room physicians in determining the wound healing potential of burns. The Company also notes the following:
- The Company will pursue a De Novo classification request from the FDA for use of the DeepView® System in burn care and expects to submit its De Novo request by June 2025.
- It has worked with the FDA through numerous pre-submission meetings for guidance and the advancement of its DeepView AI®- Burn technology.
“After completing the image analysis and truthing of our U.S. Burn Pivotal Study, I am highly encouraged by the sensitivity and specificity results of our DeepView® System when compared to the wound healing potential as determined by treating physicians,” stated Dr. J. Michael DiMaio, MD, Chairman of the Board at Spectral AI. “These results underscore the transformative impact of the DeepView® System and its attendant use of artificial intelligence in burn wound care, offering clinicians an immediate, data-driven assessment tool that can improve treatment decisions and patient outcomes. The dedication of our team in reaching this critical FDA submission milestone cannot be overstated, and we remain committed to bringing this breakthrough technology to burn care institutions across the U.S.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. The DeepView® System is a predictive device that offers clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView® System is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView® System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
When will Spectral AI (MDAI) submit its FDA De Novo request for the DeepView System?
How many data points does Spectral AI's (MDAI) DeepView System use for burn assessment?
What is the main function of Spectral AI's (MDAI) DeepView System?
When did Spectral AI (MDAI) receive FDA Breakthrough Device Designation for DeepView?
What type of regulatory approval is Spectral AI (MDAI) seeking for the DeepView System?
